Sogroya Side Effects

Generic name: somapacitan-beco

Medically reviewed by Drugs.com. Last updated on Jun 29, 2024.

Note: This document provides detailed information about Sogroya.

Applies to somapacitan-beco: subcutaneous solution Side Effects associated with somapacitan-beco. Some dosage forms listed on this page may not apply specifically to the brand name Sogroya.

Applies to somapacitan-beco: subcutaneous solution.

Precautions

It is very important that your doctor check your progress at regular visits to make sure this medicine is working properly. Blood tests may be needed to check for unwanted effects.

This medicine may increase your risk for cancer, including skin cancer. Call your doctor right away if you have changes in your moles, birthmarks, or color of the skin.

Check with doctor right away if you have anxiety, blurred vision, chills, cold sweats, coma, confusion, cool, pale skin, depression, dizziness, fast heartbeat, headache, increased hunger, nausea, nervousness, nightmares, seizures, shakiness, slurred speech, or unusual tiredness or weakness. These may be symptoms of hyperglycemia (high blood sugar).

This medicine may increase pressure in your head (intracranial hypertension). Check with your doctor right away if you have confusion, headache, severe nausea, vomiting, or vision changes.

This medicine may cause serious allergic reactions, including anaphylaxis and angioedema, which can be life-threatening and require immediate medical attention. Tell your doctor right away if you have a rash, itching, hoarseness, trouble breathing, trouble swallowing, or any swelling of your hands, face, or mouth after receiving this medicine.

This medicine may cause fluid retention (excess fluid build-up in the body). Call your doctor right away if you have burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings, joint or muscle pain, swelling of the hands, ankles, feet, or lower legs, or weight gain.

Check with your doctor right away if you have darkening of the skin, diarrhea, dizziness, fainting, loss of appetite, mental depression, nausea, skin rash, unusual tiredness or weakness, or vomiting. These may be symptoms of an adrenal gland problem (eg, hypoadrenalism).

Thyroid problems (eg, hypothyroidism) may occur during treatment with this medicine. Call your doctor right away if you have constipation, depressed mood, dry skin and hair, feeling cold, hair loss, hoarseness or husky voice, muscle cramps and stiffness, slow heartbeat, weight gain, or unusual tiredness or weakness.

Check with your doctor right away if you have bloating, chills, constipation, darkened urine, fast heartbeat, fever, indigestion, loss of appetite, nausea, pain in the stomach, side, or abdomen, possibly radiating to the back, vomiting, or yellow eyes or skin. These may be symptoms of pancreatitis (swelling of the pancreas).

Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.

Serious side effects of Sogroya

Along with its needed effects, somapacitan-beco (the active ingredient contained in Sogroya) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking somapacitan-beco:

Other side effects of Sogroya

Some side effects of somapacitan-beco may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

For healthcare professionals

Applies to somapacitan-beco: subcutaneous solution.

General adverse events

In pediatric patients with growth hormone deficiency (GHD): Common adverse reactions occurring in 5% or more of patients receiving this drug include nasopharyngitis, headache, fever, extremity pain, and injection site reactions.

In adult patients with GHD: Adverse reactions occurring in over 2% of patients treated with this drug comprise back pain, joint pain, indigestion, sleep disturbances, dizziness, tonsillitis, peripheral edema, vomiting, adrenal insufficiency, high blood pressure, elevated blood creatine phosphokinase levels, weight gain, and anemia.^[Ref]

Cardiovascular

• Common (1% to 10%): Hypertension^[Ref]

Dermatologic

• Common (1% to 10%): Rash, urticaria
• Uncommon (0.1% to 1%): Lipohypertrophy, pruritus^[Ref]

Endocrine

• Common (1% to 10%): Adrenal insufficiency, hypoadrenalism, hypothyroidism^[Ref]

Gastrointestinal

• Common (1% to 10%): Dyspepsia, nausea/vomiting, diarrhea, gastroenteritis
• Frequency not reported: Pancreatitis^[Ref]

Nausea/vomiting included vomiting (4.5%) and nausea (1.5%); Diarrhea included diarrhea (2.3%), gastroenteritis viral (1.5%), and gastrointestinal viral infection (0.8%).^[Ref]

Hematologic

• Common (1% to 10%): Anemia^[Ref]

Hypersensitivity

• Frequency not reported: Severe hypersensitivity^[Ref]

Local

• Common (1% to 10%): Injection site reaction
• Frequency not reported: Lipohypertrophy, lipoatrophy^[Ref]

Injection site reaction included injection site bruising (1.5%), injection site pain (1.5%), injection site hematoma (1.5%), injection site reaction (0.8%), and injection site swelling (0.8%).^[Ref]

Metabolic

• Very common (10% or more): Elevated phosphate (17.5%)
• Common (1% to 10%): Elevated creatine phosphokinase, blood creatinine kinase increase, weight increased, hyperglycemia
• Frequency not reported: Glucose intolerance, diabetes mellitus, fluid retention^[Ref]

Elevated phosphate and creatine phosphokinase occurred intermittently and were non-progressive.^[Ref]

Musculoskeletal

• Very common (10% or more): Back pain (10%)
• Common (1% to 10%): Arthralgia, myalgia, muscle stiffness
• Uncommon (0.1% to 1%): Joint stiffness^[Ref]

Nervous system

• Very common (10% or more): Headache (12.1%)
• Common (1% to 10%): Sleep disorder, dizziness, paresthesia
• Uncommon (0.1% to 1%): Carpal tunnel syndrome
• Frequency not reported: Intracranial hypertension^[Ref]

Oncologic

• Frequency not reported: Neoplasms^[Ref]

Other

• Common (1% to 10%): Peripheral edema, pyrexia, fatigue, asthenia, influenza
• Frequency not reported: Increased mortality in patients with acute critical illness^[Ref]

Pyrexia included pyrexia (8.3%) and hyperthermia (0.8%); pain in extremity included pain in extremity (9.1%) and growing pains (0.8%).^[Ref]

Respiratory

• Very common (10% or more): Nasopharyngitis (16.7%)
• Common (1% to 10%): Tonsillitis, bronchitis, upper respiratory tract infection^[Ref]

Nasopharyngitis included nasopharyngitis (11.4%), rhinitis (3.8%), pharyngitis streptococcal (0.8%), acute sinusitis (0.8%), nasal congestion (0.8%), pharyngitis (0.8%), and sinusitis (0.8%).^[Ref]

See also:

Further information

Sogroya side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer